timothy sykes logo

Stock News

Theratechnologies Stock Soars: Implications for Investors

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 3/26/2025, 11:37 am ET 3/26/2025, 11:37 am ET | 6 min 6 min read
Theratechnologies Stock Soars: Implications for Investors Thumbnail

Theratechnologies Inc. is experiencing a notable boost with stocks trading up by 12.34 percent on Wednesday, driven largely by positive developments such as potential strategic partnerships and promising advancements in their drug pipeline.

Exciting Development:

  • FDA approval for EGRIFTA WR™, a game-changer in treating excess abdominal fat in adults with HIV and lipodystrophy, is set to replace its predecessor, EGRIFTA SV, with improved attributes.

Candlestick Chart

Live Update At 11:37:22 EST: On Wednesday, March 26, 2025 Theratechnologies Inc. stock [NASDAQ: THTX] is trending up by 12.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Revenue jumped to $25M in Q4, up from $23.45M last year, marking a significant achievement for Theratechnologies.

  • New data from the PROMISE-US trial emphasized the effectiveness of ibalizumab for patients dealing with multidrug-resistant HIV, showcased at a major conference.

  • Theratechnologies’ research on cardiovascular risk analysis has exposed the limitations of BMI as a lone risk factor, highlighting the value of considering excess visceral fat.

Financial Overview:

As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” Successful trading requires not only a solid understanding of market dynamics but also the discipline to wait for the right opportunities. Traders who meticulously plan and exhibit patience are often the ones who see the biggest returns.

Theratechnologies has enjoyed a fruitful year with impressive growth in revenues, climbing to $25M in the latest quarter. The increase not only surpassed last year’s figures but also pointed towards their strategic advancements in innovation. The EBIT margin stands at 11.8%, with a gross margin floating impressively at 76.2%. Numbers like these resonate well with investors, ensuring they keep a close eye on this stock. But, there are some storm clouds too. The profit margin is negative at -9.67%. This foundation tells a picture of strong revenue-generating ability but a struggle with profitability.

Despite such constraints, the FDA approval offers a beacon of potential revenue growth. EGRIFTA WR™ aligns with efforts to fine-tune formulations for better efficacy, tapping into underserved areas, pointing toward potential profitability improvements.

Recent Chart Performance:

Reviewing recent stock prices offers insight into investor sentiments. The stock price exhibited significant bursts, peaking around $2 before dipping, highlighting volatility. On Mar 26, 2025, THTX opened at $1.99 and ended at $1.73, indicating market apprehension or profit-taking possibly after substantial gains. Intraday trading offers a more dramatic observation when evaluating price ranges.

The initial excitement reached a high of $2.12 but retracted to $1.65, aligning with narratives of heightened anticipation followed by realism adjustments. Such shifts underline the importance of attentive trading when dealing with biotech innovations, where breakthrough approvals propel stock momentum upward.

Analysis of Key Events:

FDA Milestone Approval:

Consider the FDA’s nod for EGRIFTA WR™, a story of strategic progression and clinical achievement. This development opens a hopeful chapter for those battling lipodystrophy. Transitioning from daily to weekly administration aids patient adherence and satisfaction, a cornerstone to product uptake. FDA approval isn’t merely about compliance; it provides trust and broadened entry into the market. With EGRIFTA WR™ poised to replace its predecessor, SV, there’s potential for increased operational efficiencies and enhanced patient outcomes.

More Breaking News

PROMISE-US Trial Revelations:

The PROMISE-US trial data exhibits Theratechnologies’ commitment to pioneering better treatment landscapes. Presented at a well-regarded conference, the findings echo resilience in their R&D approach, underscoring the promise ibalizumab offers to individuals facing treatment challenges. These developments boost investor confidence, widening their therapeutic impact. Retaining market value boils down to translating research into visible commercial footprints, a challenge THTX seems to embrace.

Unraveling the Data:

Theratechnologies underscores the role of excess visceral fat over traditional BMI measures. By showcasing detailed cardiovascular implications, they step into a leadership position in redefining health metrics. The market often cherishes innovations that challenge the status quo, potentially holding a key to unlocking stock movement corridors. As awareness grows, the stock stands to benefit from insights beyond conventional risk analyses.

Conclusion:

In conclusion, Theratechnologies shines under the spotlight thanks to strategic FDA approvals, buoying trader expectations in market skids. While concerns about profitability linger, the increased revenue trajectory and promising drug data paint an optimistic picture. With ingenuity along the R&D domain, coupled with the promise of a healthier bottom line, Theratechnologies colorfully illustrates a journey towards transforming trader prospects. Such strides in regulated environments echo robust growth potential, reflective in their stock’s pulse, rebounding with optimism against the backdrop of medical triumphs. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Therefore, Theratechnologies’ stock narrative is kaleidoscopic, juxtaposed with innovation milestones and market volatility – a tale told in ticks and trends, urging traders to watch closely.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”